BCRX logo

BioCryst Pharmaceuticals (BCRX)

Profile

Full Name

BioCryst Pharmaceuticals, Inc.

Ticker Symbol

BCRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

March 4, 1994

Indexes

Not included

Website

http://www.biocryst.com

Employees

580

Key Details

Price

$7.40(+5.11%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$450.71M(+36.00% YoY)

Annual EPS

-$0.43(+63.56% YoY)

PE ratio

-

Next earnings date

May 6, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$7.40
BCRX price is $7.40

30-Day Relative Volume

0.95
BCRX 30-day relative volume is 0.95

Price Performance

Price Most recent change

+5.11%
BCRX price was up +5.11% on Apr 15, 2025

Price YTD change

-1.6%
BCRX price is down -1.6% since January 1st

Price 1-year change

+60.52%
BCRX price is up +60.52% year-on-year

Price 3-year change

-35.03%
BCRX price is down -35.03% over the past 3 years

Price Range

Price All-time high

$37.25
BCRX price is currently -80.13% below its historical high of $37.25

Price 3-year low

$4.03
BCRX price is currently +83.62% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$1.55B
BCRX market capitalization is $1.55 billion

Market cap 3-year change

-26.84%
BCRX market capitalization is down -26.84% over the past 3 years

Market cap All-time high

$3.65B
BCRX market capitalization is currently -57.62% below its historical high of $3.65 billion

Market cap sector rank

80.84%
BCRX market capitalization is higher than 80.84% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.27%
BCRX shares outstanding is up +1.27% year-on-year

Shares Outstanding 3-Year Change

+12.6%
BCRX shares outstanding is up +12.6% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.84
BCRX beta is 0.84

200-day SMA

$7.70
BCRX price is currently -3.83% below its 200-day simple moving average

50-day SMA

$7.97
BCRX price is currently -7.14% below its 50-day simple moving average

RSI

50.28
BCRX 14-day relative strength index is 50.28

Volume

0.95
BCRX 30-day relative volume is 0.95

ATR

$0.45
BCRX average true range is $0.45

10-day Historical Volatility

75.47%
BCRX 10-day historical volatility is 75.47%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$450.71M
BCRX annual revenue is $450.71 million

Revenue Analysts estimate

$563.58M
BCRX annual revenue is currently -20.03% lower than the consensus analysts' forecast

Revenue 1-year change

+36%
BCRX annual revenue is up +36% year-on-year

Revenue Sector rank

73.52%
BCRX annual revenue is higher than 73.52% of companies in Healthcare sector

EPS

EPS

-$0.43
BCRX annual earnings per share is -$0.43

EPS Analysts estimate

-$0.05
BCRX annual earnings per share is currently +714.39% higher than the consensus analysts' forecast

EPS 1-year change

+63.56%
BCRX annual earnings per share is up +63.56% year-on-year

EPS Sector rank

71%
BCRX annual earnings per share is higher than 71% of companies in Healthcare sector

Profit

Gross profit

$438.23M
BCRX annual gross profit is $438.23 million

Gross margin

97.23%
BCRX annual gross profit margin is 97.23%

Operating profit

-$2.54M
BCRX annual operating income is -$2.54 million

Operating margin

-0.56%
BCRX annual operating profit margin is -0.56%

Net income

-$88.88M
BCRX annual net profit is -$88.88 million

Net margin

-19.72%
BCRX annual net profit margin is -19.72%

Expenses

Total expenses

$453.25M
BCRX annual total expenses is $453.25 million

Operating expenses

$440.77M
BCRX annual total operating expenses is $440.77 million

Cost of goods sold

$12.48M
BCRX annual cost of goods sold is $12.48 million

Selling, general & administrative expenses

$266.13M
BCRX annual SGA is $266.13 million

Depreciation and amortization

$1.25M
BCRX annual depreciation & amortization is $1.25 million

Interest expense

$98.52M
BCRX annual interest expense is $98.52 million

Income tax

$1.93M
BCRX annual income tax is $1.93 million

EBIT & EBITDA

EBIT

$11.56M
BCRX annual earnings before interest & taxes is $11.56 million

EBITDA

$12.81M
BCRX annual EBITDA is $12.81 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$490.42M
BCRX annual total assets is $490.42 million

Non current assets

$68.45M
BCRX annual long term assets is $68.45 million

Current assets

$421.97M
BCRX annual total current assets is $421.97 million

Cash and cash equivalents

$104.71M
BCRX annual cash & cash equivalents is $104.71 million

Accounts receivable

$79.07M
BCRX annual accounts receivable is $79.07 million

Inventory

$8.09M
BCRX annual inventory is $8.09 million

Liabilities

Total liabilities

$966.35M
BCRX annual total liabilities is $966.35 million

Long term liabilities

$805.97M
BCRX annual total long term liabilities is $805.97 million

Current liabilities

$160.38M
BCRX annual total current liabilities is $160.38 million

Accounts payable

$11.64M
BCRX annual accounts payable is $11.64 million

Debt

Total debt

$808.74M
BCRX annual total debt is $808.74 million

Total debt 1-year change

-1.99%
BCRX annual total debt is down -1.99% year-on-year

Long term debt

$805.97M
BCRX annual long term debt is $805.97 million

Short term debt

$2.77M
BCRX annual short term debt is $2.77 million

Equity & Capital

Shareholders equity

-$475.93M
BCRX annual stockholders equity is -$475.93 million

Book value

-$475.93M
BCRX annual book value is -$475.93 million

Retained earnings

-$1.77B
BCRX annual retained earnings is -$1.77 billion

Working capital

$261.58M
BCRX annual working capital is $261.58 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$52.02M
BCRX annual cash flow from operations is -$52.02 million

Cash from operations 1-year change

+45.32%
BCRX annual cash flow from operations is up +45.32% year-on-year

Cash from investing

$52.59M
BCRX annual cash flow from investing activities is $52.59 million

Cash from investing 1-year change

+140%
BCRX annual cash flow from investing activities is up +140% year-on-year

Cash from financing

-$5.76M
BCRX annual cash flow from financing activities is -$5.76 million

Cash from financing 1-year change

-117.73%
BCRX annual cash flow from financing activities is down -117.73% year-on-year

CAPEX

CAPEX

$1.12M
BCRX annual capital expenditures is $1.12 million

CAPEX 1-year change

-48.15%
BCRX annual capital expenditures is down -48.15% year-on-year

Free Cash Flow

Free cash flow

-$53.14M
BCRX annual free cash flow is -$53.14 million

Free cash flow 1-year change

+45.39%
BCRX annual free cash flow is up +45.39% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

97.23%
BCRX annual gross profit margin is 97.23%

Operating margin

-0.56%
BCRX annual operating profit margin is -0.56%

Net margin

-19.72%
BCRX annual net profit margin is -19.72%

ROA & ROE

ROA

-17.65%
BCRX annual return on assets is -17.65%

ROE

18.68%
BCRX annual return on equity is 18.68%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BCRX price to earnings ratio value is unknown

PE ratio Sector rank

-
BCRX price to earnings ratio is unknown

PB Ratio

PB ratio

-3.25
BCRX price to book ratio is -3.25

PB ratio Sector rank

5.35%
BCRX price to book ratio is higher than 5.35% of companies in Healthcare sector

PS Ratio

PS ratio

3.43
BCRX price to sales ratio is 3.43

PS ratio Sector rank

57.05%
BCRX price to sales ratio is higher than 57.05% of companies in Healthcare sector

Enterprise value

Enterprise value

$2.25B
BCRX enterprise value is $2.25 billion

Enterprise value Sector rank

83.04%
BCRX enterprise value is higher than 83.04% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

175.70
BCRX EV/EBITDA is 175.70

EV/EBITDA Sector rank

99.3%
BCRX EV/EBITDA is higher than 99.3% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.63
BCRX annual current ratio is 2.63

Quick ratio

2.58
BCRX annual quick ratio is 2.58

Leverage

Debt to equity

-1.67
BCRX annual debt to equity ratio is -1.67

Interest coverage ratio

0.12
BCRX annual interest coverage ratio is 0.12

Risk & Stability

Piotroski F-Score

3
BCRX piotroski f-score is 3

Altman Z-Score

-2.46
BCRX altman z-score is -2.46

Analyst ratings

Recent major analysts updates

Apr 11, 25 RBC Capital
Outperform
Apr 10, 25 Needham
Buy
Mar 3, 25 Citizens Capital Markets
Market Outperform
Feb 25, 25 RBC Capital
Outperform
Feb 25, 25 HC Wainwright & Co.
Buy
Feb 25, 25 Citizens Capital Markets
Market Outperform
Jan 31, 25 JMP Securities
Market Outperform
Jan 13, 25 Needham
Buy
Jan 13, 25 Evercore ISI Group
Outperform
Dec 17, 24 Needham
Buy

Institutional Ownership

Similar stocks

KNSA logo
Kiniksa Pharmaceuticals (KNSA)
CGON logo
CG Oncology (CGON)
ASTH logo
Astrana Health (ASTH)
ARQT logo
Arcutis Biotherapeutics (ARQT)
UFPT logo
UFP Technologies (UFPT)
GLPG logo
Galapagos NV (GLPG)
ATRC logo
AtriCure (ATRC)
CNTA logo
Centessa Pharmaceuticals (CNTA)
ANIP logo
ANI Pharmaceuticals (ANIP)
  • What is the ticker symbol for BioCryst Pharmaceuticals?
  • Does BioCryst Pharmaceuticals pay dividends?
  • What sector is BioCryst Pharmaceuticals in?
  • What industry is BioCryst Pharmaceuticals in?
  • What country is BioCryst Pharmaceuticals based in?
  • When did BioCryst Pharmaceuticals go public?
  • Is BioCryst Pharmaceuticals in the S&P 500?
  • Is BioCryst Pharmaceuticals in the NASDAQ 100?
  • Is BioCryst Pharmaceuticals in the Dow Jones?
  • When was BioCryst Pharmaceuticals's last earnings report?
  • When does BioCryst Pharmaceuticals report earnings?
  • Should I buy BioCryst Pharmaceuticals stock now?

What is the ticker symbol for BioCryst Pharmaceuticals?

The ticker symbol for BioCryst Pharmaceuticals is NASDAQ:BCRX

Does BioCryst Pharmaceuticals pay dividends?

No, BioCryst Pharmaceuticals does not pay dividends

What sector is BioCryst Pharmaceuticals in?

BioCryst Pharmaceuticals is in the Healthcare sector

What industry is BioCryst Pharmaceuticals in?

BioCryst Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is BioCryst Pharmaceuticals based in?

BioCryst Pharmaceuticals is headquartered in United States

When did BioCryst Pharmaceuticals go public?

BioCryst Pharmaceuticals's initial public offering (IPO) was on March 4, 1994

Is BioCryst Pharmaceuticals in the S&P 500?

No, BioCryst Pharmaceuticals is not included in the S&P 500 index

Is BioCryst Pharmaceuticals in the NASDAQ 100?

No, BioCryst Pharmaceuticals is not included in the NASDAQ 100 index

Is BioCryst Pharmaceuticals in the Dow Jones?

No, BioCryst Pharmaceuticals is not included in the Dow Jones index

When was BioCryst Pharmaceuticals's last earnings report?

BioCryst Pharmaceuticals's most recent earnings report was on Feb 24, 2025

When does BioCryst Pharmaceuticals report earnings?

The next expected earnings date for BioCryst Pharmaceuticals is May 6, 2025

Should I buy BioCryst Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page